Sector: Health Care
Director information for 10X GENOMICS INC CLASS A (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Alan V. Mateo | Advisor; Director | 64 | ["Executive Vice President, Global Sales at Veeva Systems Inc.","Executive Vice President of Field Operations at Medidata Solutions, Inc.","Experience in various executive roles at Medidata Solutions, Inc.","Northeast Sales Director for Red Pepper Software Co.","Major account executive at JD Edwards","Bachelor of Science in Computer Science and Marketing from Juniata College"] | [] | 2026 |
| Benjamin J. Hindson | Chief Scientific Officer, President and Director | 51 | [] | [] | 2026 |
| Benjamin J. Hindson, Ph.D. | Chief Scientific Officer and President | 51 | ["Co-founder of 10x Genomics, Inc.","Chief Scientific Officer and President since October 2012","Experience as President of Technology and Treasurer","Previous roles at QuantaLife and Lawrence Livermore National Laboratory","B.Sc. in Chemistry and Ph.D. in Chemistry from Deakin University"] | [] | 2026 |
| John R. Stuelpnagel | Chairman of our Board of Directors | 68 | [] | [] | 2026 |
| John R. Stuelpnagel, D.V.M. | Chairman of the Board | 68 | ["Co-founder of life sciences and pharmaceutical companies","Experience serving as a director and executive officer of other life sciences companies","Extensive experience in business"] | [] | 2026 |
| Kimberly J. Popovits | Director; Chairman of the Board | 67 | ["Senior management experience in healthcare and biotechnology","Experience with commercial strategy and capability building"] | [] | 2026 |
| Sarah A. Teichmann, Ph.D. | Director | 50 | ["Chair in Stem Cell Medicine at the University of Cambridge","Senior Research Fellow at the University of Cambridge","Previous Junior Research Fellow at University of Cambridge","Previous Teaching Fellow at University of Cambridge","Previous Director of Studies at University of Cambridge","Previous Director of Research at University of Cambridge’s Cavendish Laboratory","Co-chair of the Human Cell Atlas Organizing Committee","Co-chair of the board of directors of Human Cell Atlas, Inc.","Vice President, Translational Research, Respiratory & Immunology at Glaxo Smith Kline","Co-founder and Chief Scientific Officer of EnsoCell Therapeutics","Previous Head of Cellular Genetics at the Wellcome Sanger Institute","Previous Senior Group Leader at the Wellcome Sanger Institute","Previous Research Group Leader at EMBL","Previous Programme Leader at the MRC Laboratory of Molecular Biology","Beit Memorial Fellow at University College London","Member of the European Molecular Biology Organization","Fellow of the Academy of Medical Sciences and Royal Society","Fellow of the International Society of Computational Biology","Fellow of the American Academy of Arts and Sciences","Fellow of the National Academy of Medicine (USA)"] | [] | 2026 |
| Sarah Teichmann | Director | 50 | [] | [] | 2026 |
| Serge Saxonov | Chief Executive Officer and Director | 49 | [] | [] | 2026 |
| Serge Saxonov, Ph.D. | Chief Executive Officer | 49 | ["Co-founder of 10x Genomics, Inc.","Chief Executive Officer","Former Vice President of Applications at QuantaLife","Founding Architect and Director of research and development at 23andMe","Ph.D. in biomedical informatics from Stanford University","A.B. in applied mathematics from Harvard College"] | [] | 2026 |
| Shehnaaz Suliman | Director | 54 | [] | [] | 2026 |
| Shehnaaz Suliman, M.D., M.Phil., M.B.A. | President, Chief Executive Officer and a member of the board of directors | 54 | ["Extensive operational experience with global biopharmaceutical and life sciences companies","Expertise in business development and corporate strategy"] | [] | 2026 |
| Sri Kosaraju | Director | 48 | ["Global chair of investment banking for JPMorgan Chase & Co","President and Chief Executive Officer of Inscripta","Board member of Manus Bio","Board member of Hertz Foundation","President of Penumbra","Chief Financial Officer of Penumbra","Head of Strategy at Penumbra","Investment banking at J.P. Morgan Securities LLC"] | [] | 2026 |
